DiaMedica Therapeutics to Participate in Upcoming Investor Conferences

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a biopharmaceutical company in clinical development, has announced its participation in two significant investor conferences in New York City. The company, which focuses on developing innovative treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke, will be represented by President and CEO Rick Pauls and Chief Business Officer Dave Wambeke.

The first event is the H.C. Wainwright 27th Annual Global Investment Conference, taking place from September 8-10, 2025. DiaMedica will engage in one-on-one meetings and deliver a corporate presentation on September 9, 2025, at 2:30 PM ET. Following that, they will participate in the Lake Street Capital Markets Best Ideas Growth Conference Big 9 on September 11, 2025, which will also feature one-on-one meetings.

DiaMedica is notably advancing its lead candidate, DM199, which is a recombinant (synthetic) form of the KLK1 protein. This novel therapy has already been established in Asia as a treatment option for acute ischemic stroke, preeclampsia, and various vascular diseases, highlighting the company's commitment to addressing significant health challenges.

Investors and those interested in more information can visit DiaMedica's official website at www.diamedica.com or contact their team directly. The company's focus on serious ischemic conditions positions it as a key player in the biotech space, and participation in these conferences reflects its strategic approach to engaging with investors while showcasing its innovative therapeutic advancements.

For further inquiries, contact Scott Kellen, CFO, or Mike Moyer at LifeSci Advisors. Media inquiries can be directed to Madelin Hawtin at LifeSci Communications.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) presents an interesting investment opportunity as it prepares for its participation in upcoming investor conferences in New York City. As a clinical-stage biopharmaceutical firm focused on addressing significant health challenges like preeclampsia, fetal growth restriction, and acute ischemic stroke, DiaMedica's innovative approach with its lead candidate DM199 garners attention in the pharmaceutical sector.

Investors should consider attending the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, where CEO Rick Pauls and CBO Dave Wambeke will provide valuable insights during one-on-one meetings and a corporate presentation. Given the rising menace of ischemic diseases worldwide, DM199’s novel formulation as the first pharmaceutically active recombinant KLK1 protein positions DiaMedica to capture a vital market segment.

Moreover, the subsequent participation at the Lake Street Capital Markets Best Ideas Growth Conference highlights the company's commitment to maintaining investor relations and transparency. These forums not only provide opportunities for potential investment but also signals that DiaMedica is engaged in a growth trajectory, essential for stakeholder confidence.

Furthermore, considering the increasing recognition of innovative biopharmaceutical companies within the investor community, those interested in long-term plays within healthcare should monitor DiaMedica. The success of DM199 could pave the way for substantial revenue growth, contingent on positive clinical trial results and potential commercialization strategies.

In summary, as DiaMedica Therapeutics approaches these investor-centric events, potential investors are encouraged to assess the company's therapeutic innovations and their implications in addressing unmet medical needs. Aligning investment strategies with clinical milestones and market potential could yield favorable outcomes. Keep a close watch on DiaMedica’s developments, as they are poised for a transformative journey in the biopharmaceutical landscape.